(Reuters) - Johnson & Johnson reported better-than-expected quarterly results on Tuesday, as pharmaceutical sales rebounded with the help of newer products, including treatments for prostate cancer and hepatitis C.
The company earned $3.0 billion, or $1.05 per share, in the third quarter, compared with $3.2 billion, or $1.15 per share, in the year-earlier period.
Excluding special items, the diversified healthcare company earned $1.25 per share. Analysts, on average, expected $1.21 per share, according to Thomson Reuters I/B/E/S.
Revenue rose 6.5 percent to $17.1 billion, topping Wall Street expectations of $16.97 billion. Sales would have risen 10.8 percent if not for the stronger dollar, which hurts the value of revenues in overseas markets.
J&J slightly raised its full-year profit forecast to between $5.05 and $5.10 per share from $5.00 to $5.07 per share.
Company shares rose 1.1 percent to $69.40 in premarket trading.
(Reporting by Ransdell Pierson; Editing by Gerald E. McCormick and Jeffrey Benkoe)
Copyright 2012 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.post grad arpaio carol burnett neil degrasse tyson neil degrasse tyson davy jones death born this way foundation
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.